Cash Flow Statement (Annual)
BSFT / BroadSoft, Inc. Cash Flow Statement shows changes in cash positions over time. Cash Flow Statement data includes Cash from Operating Activities (CFOP), Cash from Investing Activities, and Cash from Financing Activities.
All numbers are times 1,000 except per share units.
|Supplemental Cash Flow Information|
|Income Taxes Paid||1,977||1,261||385||1,363||422||1,678||2,377||3,572|
|Interest Paid Net||1,451||655||1,032||905||1,895||1,801||1,418||3,000|
|Noncash Or Part Noncash Acquisition Fixed Assets Acquired1||-||-||-||1,800||528||688||2,153||1,523|
|Net Cash Provided By Used In Investing Activities|
|Increase Decrease In Restricted Cash||-708||-29||-14||-375||-3||-564||0||-|
|Finite Lived Intangible Assets Purchase Accounting Adjustments||-||-809||-905||0||0||-||-||-|
|Proceeds From Sale Of Available For Sale Securities||-||-||11,267||3,000||0||10,000||128,827||106,355|
|Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities||-||-||46,962||171,458||103,240||109,042||69,677||69,085|
|Payments To Acquire Marketable Securities||-||18,673||137,305||179,886||117,067||122,991||252,467||281,111|
|Payments To Acquire Businesses Net Of Cash Acquired||-806||2,191||16,748||25,177||37,793||3,650||21,172||34,678|
|Net Cash Provided By Used In Investing Activities||694||-24,274||-99,136||-34,153||-57,406||-17,558||-88,011||-156,087|
|Payments To Acquire Property Plant And Equipment||769||2,630||2,421||3,923||5,789||10,523||12,876||15,738|
|Net Cash Provided By Used In Financing Activities|
|Proceeds From Warrant Exercises||-||100||-||-||-||-||-||-|
|Proceeds From Issuance Of Common Stock||-||9,932||-||-||-||-||-||-|
|Proceeds From Issuance Initial Public Offering||-||39,951||-||-||-||-||-||-|
|Payments For Repurchase Of Preferred Stock And Preference Stock||-||4,320||-||-||-||-||-||-|
|Repayments Of Long Term Debt||2,753||16,697||1,626||382||969||0||0||-|
|Proceeds From Stock Options Exercised||69||762||3,943||2,459||1,285||710||6,187||15,181|
|Net Cash Provided By Used In Financing Activities||-2,684||29,203||117,431||-121||4,831||-4,135||118,918||-2,467|
|Excess Tax Benefit From Share Based Compensation Financing Activities||-||-||61||579||7,492||2,950||1,809||296|
|Taxes Paid On Vesting Of Rsus||-||525||574||2,198||2,977||7,795||10,297||17,944|
|Proceeds From Issuance Of Convertible Senior Notes Net Of Issuance Costs||-||-||115,688||0||0||-||-||-|
|Payments For Repurchase Of Common Stock||-||-||-||-||0||0||25,002||0|
|Proceeds From Issuance Of Senior Long Term Debt||-||-||-||-||0||0||194,822||0|
|Repayments Of Senior Debt||-||-||-||-||0||0||48,601||0|
|Effect Of Exchange Rate On Cash And Cash Equivalents||79||70||-52||149||-38||-1,389||-1,379||-1,407|
|Cash And Cash Equivalents Period Increase Decrease||8,516||24,385||46,818||-3,527||-20,679||31,677||74,314||-92,864|
|Cash And Cash Equivalents At Carrying Value||-||-||94,072||90,545||69,866||101,543||175,857||82,993|
|Net Cash Provided By Used In Operating Activities|
|Net Cash Provided By Used In Operating Activities||10,427||19,386||28,575||30,598||31,934||54,759||44,786||67,097|
|Increase Decrease In Operating Capital|
|Increase Decrease In Other Operating Assets||1,004||463||511||16,414||1,128||4,056||4,896||7,606|
|Increase Decrease In Deferred Revenue||18,869||19,217||-3,240||4,013||16,473||22,911||9,099||-2,000|
|Increase Decrease In Accounts Payable And Accrued Liabilities||-3,532||630||238||-1,125||-1,799||4,655||2,234||4,815|
|Increase Decrease In Accounts Receivable||4,147||15,023||5,997||2,557||16,334||14,806||23,935||12,499|
|Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities|
|Valuation Allowance Deferred Tax Asset Change In Amount||-||-||8,946||0||0||-||-||-|
|Tax Benefit From Stock Options Exercised1||-||-||61||579||-||-||-||-|
|Change In Fair Value Of Preferred Stock Warrants And Accretion Of Debt Discount||-137||-153||-||-||-||-||-||-|
|Other Noncash Income Expense||-101||-||-24||0||0||-||-||-|
|Share Based Compensation||3,629||3,008||7,201||15,022||41,684||29,628||40,444||51,507|
|Provision For Doubtful Accounts||59||3||-56||644||149||274||4||313|
|Paid In Kind Interest||-||-||2,560||5,120||5,504||5,906||8,617||12,684|
|Excess Tax Benefit From Share Based Compensation Operating Activities||-||-||-||579||7,492||2,950||1,809||296|
|Deferred Income Taxes And Tax Credits||-||7||5||5,088||-7,058||-3,548||-2,741||-2,031|
|Amortization Of Software Licenses||1,820||1,820||1,820||2,910||2,987||3,342||2,848||3,401|
|Depreciation And Amortizations||2,209||2,348||3,119||5,242||7,822||12,391||15,836||17,993|
|Payment Of Debt Discount||-||-||-||-||0||0||1,094||0|
|Deferred Tax Expense From Stock Options Exercised||-||-||-61||-579||-7,492||-||-||-|
|Net Income Loss||-7,849||7,992||32,297||12,076||-8,874||1,012||179||816|
Peers - Prepackaged Software (7372)
ANSS / ANSYS, Inc.
APPF / AppFolio, Inc.
BNFT / Benefitfocus, Inc.
BVSN / BroadVision, Inc.
CCOI / Cogent Communications Holdings, Inc.
EXA / Exa Corp
FSNN / Fusion Telecommunications International, Inc.
HDP / Hortonworks, Inc.
INXL / INTELLINETICS, INC.
MDSO / Medidata Solutions, Inc.
MTBC / Medical Transcription Billing, Corp.
MTBCP / Medical Transcription Billing, Corp.
QUMU / Qumu Corp.
RPD / Rapid7, Inc.
TWOU / 2U, Inc.
ULTI / Ultimate Software Group, Inc. (The)
UPLD / Upland Software, Inc.
VRNS / Varonis Systems, Inc.
2018-04-18 - Asif
History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...
2018-04-16 - Asif
Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...
2018-04-16 - Asif
Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...
2018-04-15 - Asif
Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...
2018-04-12 - Asif
Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...
as of ET